(RxWiki News) The US Food and Drug Administration (FDA) has approved the first drug to treat tardive dyskinesia.
This new approval is found under the brand name Ingrezza (valbenazine). The FDA approved it to treat adults with tardive dyskinesia, a condition marked by involuntary movements, typically of the lips and tongue. These movements can result in grimacing, sticking out the tongue and smacking the lips.
Tardive dyskinesia is a serious side effect sometimes seen in those being treated with certain medications for schizophrenia and bipolar disorder.
Valbenazine may have serious side effects, the FDA noted. These potential side effects include heart rhythm problems (QT prolongation). As a result, this medication is not recommended for those with QT syndrome or abnormal heartbeats tied to a prolonged QT interval.
Valbenazine can also cause sleepiness. Those taking Ingrezza should not drive or operate heavy machinery until they know how this medication affects them.
Neurocrine Biosciences manufactures Ingrezza.